| Wissenschaftl. Titel | A Multicenter, Randomized, Open-Label, Phase3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma |
| Erkrankung |
Niere/Harnwege:
Nierenzellkrebs:
Erstlinie
|
| Kurzprotokoll | Kurzprotokoll |
| Links | Studiendokumente zum Download (roXtra) |
erstellt 24.09.2018 Student Studienregister
geändert 16.12.2024 Admin02